FDA Allows Two New Cigarettes to Hit Market
TUESDAY, June 25 (HealthDay News) -- Using its newfound authority to regulate tobacco, the U.S. Food and Drug Administration has for the first time allowed two new cigarette brands to hit the market.
The agency also rejected requests to allow the marketing of four other new tobacco products it did not name.
The FDA first gained regulatory purview over tobacco products in 2009 under the Family Smoking Prevention and Tobacco Control Act. Therefore, "new tobacco products under FDA's authority cannot come to market without FDA's review," FDA commissioner Dr. Margaret Hamburg explained during an afternoon news conference Tuesday.
The cigarettes the FDA allowed are both Lorillard Tobacco Co. products -- Newport Non-Menthol Gold Box 100s and Newport Non-Menthol Gold Box.
Because these products are essentially "equivalent" to approved products already being marketed, they "do not raise new questions of public health" and can be sold to U.S. consumers, explained Mitchell Zeller, director of FDA's Center for Tobacco Products.
He stressed that allowing the sale of these cigarettes does not mean that they are safer or less harmful than cigarettes already on the market.
"An FDA product order is not a finding by the FDA that the product is considered safe or safer than its predicate product, or less harmful in general," he said. "In addition, the companies cannot say their products are 'FDA-approved.'"
The agency rejected four new tobacco products because they determined that they were not similar enough to existing products already on the market.
"The applicant [also] did not adequately show that the new product did not raise new questions of public health," Zeller said at the news briefing.
By law, the FDA cannot release the names of the manufacturers of the rejected products or what types of products they were, he added.
For more on tobacco regulation, visit the U.S. Food and Drug Administration.
SOURCES: June 25, 2013, news conference with: Margaret Hamburg, M.D., commissioner, U.S. Food and Drug Administration; Mitchell Zeller, J.D., director, Center for Tobacco Products, U.S. Food and Drug AdministrationRelated Articles
- New Treatment Approved for Rare Form of Hemophilia
October 24, 2014
- Two-Pronged Program Looks Best for Helping Smokers Quit
October 17, 2014
Learn More About Sharp
Sharp HealthCare is San Diego's health care leader with seven hospitals, two medical groups and a health plan. Learn more about our San Diego hospitals, choose a Sharp-affiliated San Diego doctor or browse our comprehensive medical services.
Copyright ©2013 HealthDay. All rights reserved.